New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTNEPT, ACST, ENZYNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:08 EDTACSTAcasti Pharma announces positive top-line pharmacokinetic results
Subscribe for More Information
September 29, 2014
08:10 EDTACSTAcasti Pharma reports CaPre Phase II trial met primary endpoint
Acasti Pharma announces successful top-line results for its Phase II double blind, placebo controlled trial, or TRIFECTA, assessing the safety and efficacy of CaPre for the treatment of patients with hypertriglyceridemia. CaPre, Acasti's investigational new drug candidate, is composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders. CaPre successfully met the trial's primary endpoint achieving a statistically significant mean placebo-adjusted decrease in triglycerides from baseline to week-12, with reductions of 36.4% for 1 gram and 38.6% for 2 grams.
September 23, 2014
08:22 EDTNEPTNeptune reaches annualized production capacity of 100 metric tons at Sherbrooke
Neptune Technologies announces that its Sherbrooke plant is now operating at an annualized production capacity of 100 metric tons and customer shipments of Neptune manufactured krill oil products have commenced.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use